ArticleCancer immunology, immunotherapy : CII2006
Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique.
Article in Cancer immunology, immunotherapy : CII, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Guideline
- Anti-Zic4- and Anti-NMDAR-Positive Patients and Their Correlation with Clinical Course and Image Diagnostic Findings-Case Reports.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Initial screening for neuronal autoantibodies and their putative impact on survival in patients with small-cell lung cancer.Thoracic cancer · 2024Article
- Article
- NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer.Nature communications · 2018Article
- Article
- Negative commercial screening test for paraneoplastic antibodies in a case of opsoclonus.Neurology(R) neuroimmunology & neuroinflammation · 2017Article
- Derivation of a bronchial genomic classifier for lung cancer in a prospective study of patients undergoing diagnostic bronchoscopy.BMC medical genomics · 2015Article
- Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy.Molecular cancer · 2011Review
- Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo).Cancer immunology, immunotherapy : CII · 2010Article
- Onconeural antibodies in sera from patients with various types of tumours.Cancer immunology, immunotherapy : CII · 2009Article
- CRMP5 antibodies in patients with small-cell lung cancer or thymoma.Cancer immunology, immunotherapy : CII · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The presence of circulating antineuronal antibodies has been associated with paraneoplastic neurological syndromes (PNS). Ri antibodies are often associated with lung or breast cancer, but the prevalence of such antibodies in large cancer materials is largely unknown. We used a highly sensitive immunoprecipitation assay to study the level of Ri antibodies in blood samples from 200 patients with small cell lung cancer (SCLC), 253 patients with breast cancer and 557 patients with ovarian cancer. Two hundred blood donors and six Ri positive PNS patients served as controls. The recombinant antigen used in the immunoprecipitation assay was radiolabeled by a coupled in vitro transcription and translation (ITT) technique, enabling low levels of antibodies to be detected. None of the blood donors contained Ri antibodies, whereas all of the sera from the PNS patients were positive. Ri antibodies were present in 4.5% of the patients with SCLC, 0.8% of the patients with breast cancer and in 0.2% of the patients with ovarian cancer. Retesting of the Ri positive samples with immunofluorescense and immune blot showed that the immunoprecipitation technique was more sensitive than the other immune assays. Ri antibodies were not associated with PNS in the patients with breast or ovarian cancer. Neurological data were not available for the SCLC patients, but in these, Ri antibodies were not associated with survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.